title: Effects of Helicobacter pylori eradication on proteinuria: a prospective study.
abstract: BACKGROUND
  Helicobacter pylori is one of the most common bacterial infections, seen in humans worldwide and its possible relationship to different diseases is a focus of attention nowadays. The aim of this study was to analyse the effects of H. Pylori eradication on proteinuria.
  
  
  METHODS
  Ninety-nine patients suffering from dyspeptic complaints were recruited in this prospective study. The patients were divided into two groups according to the presence of H. pylori infection. Thus, a total of 67 H. pylori positive and 32 H. pylori negative patients were studied. The H. pylori positive patients' group was divided into two groups according to response toH. pylori eradication treatment. A total of three groups were formed, viz; group 1 comprises of patients who are H. pylori positive and responds positively toH. pylori eradication therapy, group 2 comprises of patients who are H. pylori positive and responds negatively toH. pylori eradication therapy and group 3 is the control group and comprises of patients that are H. pylori negative. Urine samples to obtain the protein/creatinine ratio were collected initially and at the end of the study from all patients.
  
  
  RESULTS
  Mean difference levels (pre- and post-treatment difference) of urine protein/creatinine ratio was 0.055 ± 0.13 in group 1. The ratio was - 0.0007 ± 0.0067 in group 2 and - 0.0022 ± 0.008 in group 3. A statistically significant difference was found in group 1 compared to the other groups in terms of mean difference levels of protein/creatinine ratios (p < 0.001).
  
  
  CONCLUSIONS
  As a result of our study, treatment of H. pylori eradication significantly reduced the proteinuria within the normal limits.
authors.affiliation: Department of Gastroenterology, Harran University School of Medicine, Şanlıurfa, Turkey.
authors.forename: Timucin
authors.initials: T
authors.lastname: Aydogan
authors.forename: Turgay
authors.initials: T
authors.lastname: Ulas
authors.forename: Yusuf
authors.initials: Y
authors.lastname: Selcoki
authors.forename: Rabia
authors.initials: R
authors.lastname: Alkan
authors.forename: Omer Caglar
authors.initials: OC
authors.lastname: Yılmaz
authors.forename: Kadir Serkan
authors.initials: KS
authors.lastname: Yalcın
authors.forename: Osman
authors.initials: O
authors.lastname: Inan
authors.forename: Mehmet Sinan
authors.initials: MS
authors.lastname: Dal
authors.forename: Cansel
authors.initials: C
authors.lastname: Turkay
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D015897:Comorbidity; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000453:epidemiology* / Q000652:urine; D016480:Helicobacter pylori / Q000302:isolation & purification*; D006801:Humans; D008297:Male; D015995:Prevalence; D011446:Prospective Studies; D011507:Proteinuria / Q000196:embryology* / Q000517:prevention & control* / Q000652:urine; D016896:Treatment Outcome; D014421:Turkey / Q000453:epidemiology
chemical_list: D000900:Anti-Bacterial Agents